BACKGROUND: Glioblastoma (GBM) contains self-renewing, tumorigenic cancer stem cells (CSCs) which contribute to tumor propagation and therapeutic resistance. While the tumor microenvironment is essential to CSC self-renewal, the mechanisms by which CSCs sense and respond to microenvironmental conditions are poorly understood. Scavenger receptors are a broad class of membrane receptors that are well characterized on immune cells and instrumental in sensing apoptotic cellular debris and modified lipids. METHODS: To interrogate the role of scavenger receptors in GBM, we utilized GBM patient tissue and patient derived xenografts. CSCs were enriched using standard cell surface marker methods and validated using functional assays (proliferation, selfrenewal, tumor initiation). The role of scavenger receptors was tested using RNA interference and small molecule approaches in combination with CSC functional assays. The use of scavenger receptors as a biomarker was evaluated
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